This page was machine-translated from the Korean original and has not been reviewed by a person. Quoted source material is left in its original language and is not translated. Korean original

• Readout C143Event 2026-08-04 · Read 2026-09-28Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of the American Academy of Dermatology paper — Palvella Therapeutics, 2026-08-04 · Readout case C143

  Palvella Therapeutics cited a paper published in the Journal of the American Academy of Dermatology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C142Event 2026-07-29 · Read 2026-09-28Retrospective · abstract onlyBio

  Pharmaceutical filing citing an Epilepsia paper — Filana Therapeutics, 2026-07-29 · Readout case C142

  Filana Therapeutics cited a paper published in Epilepsia in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout 001Event 2026-07-09 · Read 2026-09-07Bio

  Dementia drug neflamapimod and CervoMed regulatory filing — when a company states "supported by a paper," three points are verified · Nature Neuroscience mouse study evaluation · 143 U.S. listed companies citing papers in 8-K filings · Tau-related national R&D

  We found and read the Nature Neuroscience paper cited by the company and checked where the paper's findings and the disclosure diverge. We also examined similar cases where U.S.-listed companies cited papers in disclosures and what happened afterward.

• Readout 004Event 2026-06-23 · Read 2026-09-17Bio

  A clinical trial has been published tracking for one year whether weight loss persists after switching from the injectable weight-loss drugs Wegovy and Mounjaro to the pill form of Foundayo · Eli Lilly paper review · Chugai Pharmaceutical Japanese patent · D&D Pharmatech, Ildong Pharmaceutical, Hanmi Pharmaceutical status

  I read a clinical paper that followed patients who switched from an injection to a pill for one year. I also checked the patent published in 2026 by the Japanese company Nihon Chugai, which is the origin of this drug, as well as the current status of oral obesity drugs from Korean companies.

• Readout C140Event 2026-05-27 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of Dermatological Treatment paper — Turn Therapeutics, 2026-05-27 · Readout case C140

  Turn Therapeutics cited a paper published in the Journal of Dermatological Treatment in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was recorded. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C141Event 2026-05-27 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Cell paper — HCW Biologics, 2026-05-27 · Readout case C141

  HCW Biologics cited a paper published in Cell in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type and written down. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C139Event 2026-05-14 · Read 2026-09-28Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Clinical and Translational Science paper — Larimar Therapeutics, 2026-05-14 · Readout case C139

  Larimar Therapeutics cited a paper published in Clinical and Translational Science in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C138Event 2026-05-07 · Read 2026-09-27Retrospective · abstract onlyBio

  Epilepsia paper cited in pharmaceutical filing — Filana Therapeutics, 2026-05-07 · Readout case C138

  Filana Therapeutics cited a paper published in Epilepsia in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C137Event 2026-05-06 · Read 2026-09-27Retrospective · abstract onlyBio

  Medical test provider filing citing Future Oncology paper — Castle Biosciences, 2026-05-06 · Readout case C137

  Castle Biosciences cited a paper published in Future Oncology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope demonstrated by the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C136Event 2026-05-06 · Read 2026-09-27Retrospective · abstract onlyBio

  Biological product filing citing a Frontiers in Medicine paper — Taysha Gene Therapies, 2026-05-06 · Readout case C136

  Taysha Gene Therapies cited a paper published in Frontiers in Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C135Event 2026-05-04 · Read 2026-09-23Retrospective · abstract onlyBio

  medical device regulatory filing citing OTO Open paper — Inspire Medical Systems, 2026-05-04 · Readout case C135

  Inspire Medical Systems cited a paper published in OTO Open as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C134Event 2026-02-11 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing Obesity paper — Viking Therapeutics, 2026-02-11 · Readout case C134

  Viking Therapeutics cited a paper published in Obesity in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month after the filing stood compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C133Event 2026-01-15 · Read 2026-09-27Retrospective · abstract onlyBio

  Biological product filing citing the Eye paper — Ocugen, 2026-01-15 · Readout case C133

  Ocugen cited a paper published in Eye in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C132Event 2026-01-08 · Read 2026-09-23Retrospective · abstract onlyBio

  Medical testing facility filing based on a Pregnancy paper — SERA Prognostics, 2026-01-08 · Readout case C132

  SERA Prognostics cited a paper published in Pregnancy as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C131Event 2025-11-06 · Read 2026-09-23Retrospective · abstract onlyBio

  Medical testing facility filing citing New England Journal of Medicine paper — Natera, 2025-11-06 · Readout case C131

  Natera cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way the paper was written and the scope it actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C130Event 2025-09-08 · Read 2026-09-27Retrospective · abstract onlyBio

  Regulatory filing by Cytokinetics citing a Journal of the American College of Cardiology paper — Readout case C130, 2025-09-08

  Cytokinetics cited a paper published in the Journal of the American College of Cardiology in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C129Event 2025-09-03 · Read 2026-09-27Retrospective · abstract onlyBio

  Regulatory filing by Cytokinetics citing a Journal of the American College of Cardiology paper — Readout case C129, 2025-09-03

  Cytokinetics cited a paper published in the Journal of the American College of Cardiology in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C128Event 2025-08-11 · Read 2026-09-27Retrospective · abstract onlyBio

  Biological product regulatory filing citing a New England Journal of Medicine paper — Sana Biotechnology, 2025-08-11 · Readout case C128

  Sana Biotechnology cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C127Event 2025-07-02 · Read 2026-09-27Retrospective · abstract onlyBio

  Cancer Cell paper cited in pharmaceutical regulatory filing — Tonix Pharmaceuticals, 2025-07-02 · Readout case C127

  Tonix Pharmaceuticals cited a paper published in Cancer Cell in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type and written down where it stood. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C126Event 2025-06-30 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a New England Journal of Medicine paper — Traws Pharma, 2025-06-30 · Readout case C126

  Traws Pharma cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way the paper was written and the scope it actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C125Event 2025-06-03 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical filing citing a *Diabetes Care* paper — Xeris Biopharma, 2025-06-03 · Readout case C125

  Xeris Biopharma cited a paper published in Diabetes Care in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past similar cases. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C124Event 2025-06-03 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing a British Journal of Dermatology paper — Traws Pharma, 2025-06-03 · Readout case C124

  Traws Pharma cited a paper published in the British Journal of Dermatology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C123Event 2025-06-02 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a JAMA Health Forum paper — Indivior Pharmaceuticals, 2025-06-02 · Readout case C123

  Indivior Pharmaceuticals cited a paper published in the JAMA Health Forum in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C122Event 2025-05-27 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a New England Journal of Medicine paper — Traws Pharma, 2025-05-27 · Readout case C122

  Traws Pharma cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. The stock price movement for one month following the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C121Event 2025-05-14 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Sleep Medicine paper — Incannex Healthcare, 2025-05-14 · Readout case C121

  Incannex Healthcare cited a paper published in Sleep Medicine in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C120Event 2025-03-19 · Read 2026-09-27Retrospective · abstract onlyBio

  Medical diagnostic laboratory regulatory filing citing a medRxiv paper — Quest Diagnostics, 2025-03-19 · Readout case C120

  Quest Diagnostics cited a paper published on medRxiv in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way the paper was written and the actual scope it demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C119Event 2025-03-13 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product filing citing a Science Translational Medicine paper — Atyr Pharma, 2025-03-13 · Readout case C119

  Atyr Pharma cited a paper published in Science Translational Medicine in a regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C118Event 2025-03-04 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product filing citing Journal of Medical Economics paper — Novavax, 2025-03-04 · Readout case C118

  Novavax cited a paper published in the Journal of Medical Economics as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which the paper was written and the actual scope it demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C117Event 2025-02-27 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of Crohn's and Colitis paper — Ventyx Biosciences, 2025-02-27 · Readout case C117

  Ventyx Biosciences cited a paper published in the Journal of Crohn's and Colitis in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month after the filing stood compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C116Event 2025-01-16 · Read 2026-09-27Retrospective · abstract onlyBio

  Biological product regulatory filing citing a Nature Communications paper — Metagenomi Therapeutics, 2025-01-16 · Readout case C116

  Metagenomi Therapeutics cited a paper published in Nature Communications as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C115Event 2025-01-13 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product regulatory filing citing a New England Journal of Medicine paper — Autolus Therapeutics, 2025-01-13 · Readout case C115

  Autolus Therapeutics cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was written in comparison to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C114Event 2025-01-13 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product filing citing a European Journal of Heart Failure paper — Tectonic Therapeutic, 2025-01-13 · Readout case C114

  Tectonic Therapeutics cited a paper published in the European Journal of Heart Failure as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C113Event 2025-01-08 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a JAMA Network Open paper — Tonix Pharmaceuticals, 2025-01-08 · Readout case C113

  Tonix Pharmaceuticals cited a paper published in JAMA Network Open as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C112Event 2024-12-12 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Diabetes Obesity and Metabolism paper — Bio-path, 2024-12-12 · Readout case C112

  Bio-path cited a paper published in Diabetes Obesity and Metabolism in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C111Event 2024-11-13 · Read 2026-09-21Retrospective · abstract onlyBio

  pharmaceutical filing citing a JAMA paper — Tonix Pharmaceuticals, 2024-11-13 · Readout case C111

  Tonix Pharmaceuticals cited a paper published in JAMA in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C110Event 2024-11-12 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing an International Journal of COPD paper — Theravance Biopharma, 2024-11-12 · Readout case C110

  Theravance Biopharma cited a paper published in the International Journal of COPD in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C109Event 2024-10-29 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing Antimicrobial Agents and Chemotherapy paper — Spero Therapeutics, 2024-10-29 · Readout case C109

  Spero Therapeutics cited a paper published in Antimicrobial Agents and Chemotherapy in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared with past cases of the same type and written accordingly. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C108Event 2024-09-16 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing Cell paper — Tonix Pharmaceuticals, 2024-09-16 · Readout case C108

  Tonix Pharmaceuticals cited a paper published in Cell in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company's manner of writing the paper and the actual scope of the paper were read in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C107Event 2024-09-09 · Read 2026-09-27Retrospective · abstract onlyBio

  Regulatory filing citing a Cell paper — Tonix Pharmaceuticals, 2024-09-09 · Readout case C107

  Tonix Pharmaceuticals cited a paper published in Cell in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type and written down where it stood. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C106Event 2024-08-08 · Read 2026-09-27Retrospective · abstract onlyBio

  Journal of Clinical Oncology paper referenced in medical testing company's regulatory filing — Natera, 2024-08-08 · Readout case C106

  Natera cited a paper published in the Journal of Clinical Oncology as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C105Event 2024-08-06 · Read 2026-09-27Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a The Lancet Regional Health - Americas paper — Emergent Biosolutions, 2024-08-06 · Readout case C105

  Emergent Biosolutions cited a paper published in The Lancet Regional Health - Americas in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which the paper was written and the actual scope it demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type and recorded where it stood. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C104Event 2024-07-31 · Read 2026-09-21Retrospective · abstract onlyBio

  Medical testing facility regulatory filing citing a Nature Medicine paper — Caredx, 2024-07-31 · Readout case C104

  Caredx cited a paper published in Nature Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C103Event 2024-07-17 · Read 2026-09-26Retrospective · abstract onlyBio

  Medical device filing citing a Journal of Cosmetic and Laser Therapy paper — Strata Skin Sciences, 2024-07-17 · Readout case C103

  Strata Skin Sciences cited a paper published in the Journal of Cosmetic and Laser Therapy as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C102Event 2024-07-08 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing National Academies Press eBooks paper — Tonix Pharmaceuticals, 2024-07-08 · Readout case C102

  Tonix Pharmaceuticals cited a paper published in National Academies Press eBooks in a regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C101Event 2024-05-15 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a paper in Headache The Journal of Head and Face Pain — Pulmatrix, 2024-05-15 · Readout case C101

  Pulmatrix cited a paper published in Headache The Journal of Head and Face Pain as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the scope the paper actually showed in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C100Event 2024-05-13 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a New England Journal of Medicine paper — Cytokinetics, 2024-05-13 · Readout case C100

  Cytokinetics cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C098Event 2024-03-28 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing a British Journal of Dermatology paper — Avalo Therapeutics, 2024-03-28 · Readout case C098

  Avalo Therapeutics cited a paper published in the British Journal of Dermatology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C097Event 2024-03-26 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product filing based on mAbs paper — Bioatla, 2024-03-26 · Readout case C097

  Bioatla cited a paper published in mAbs as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C096Event 2024-03-13 · Read 2026-09-26Retrospective · abstract onlyBio

  Neurology paper cited in pharmaceutical regulatory filing — Catalyst Pharmaceuticals, 2024-03-13 · Readout case C096

  Catalyst Pharmaceuticals cited a paper published in Neurology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past similar cases. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C095Event 2024-03-11 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a British Journal of Dermatology paper — Moonlake Immunotherapeutics, 2024-03-11 · Readout case C095

  Moonlake Immunotherapeutics cited a paper published in the British Journal of Dermatology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type, and the position was recorded. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C094Event 2024-03-07 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing an *Annals of Internal Medicine* paper — Tonix Pharmaceuticals, 2024-03-07 · Readout case C094

  Tonix Pharmaceuticals cited a paper published in the Annals of Internal Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C093Event 2024-03-05 · Read 2026-09-21Retrospective · abstract onlyBio

  pharmaceutical filing citing a New England Journal of Medicine paper — Tonix Pharmaceuticals, 2024-03-05 · Readout case C093

  Tonix Pharmaceuticals cited a paper published in the New England Journal of Medicine in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C092Event 2024-02-28 · Read 2026-09-26Retrospective · abstract onlyBio

  pharmaceutical filing citing a New England Journal of Medicine paper — Tonix Pharmaceuticals, 2024-02-28 · Readout case C092

  Tonix Pharmaceuticals cited a paper published in the New England Journal of Medicine in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C091Event 2024-02-21 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Neurology paper — Catalyst Pharmaceuticals, 2024-02-21 · Readout case C091

  Catalyst Pharmaceuticals cited a paper published in Neurology as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C090Event 2024-02-12 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Psychiatry Research paper — Tonix Pharmaceuticals, 2024-02-12 · Readout case C090

  Tonix Pharmaceuticals cited a paper published in Psychiatry Research in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C089Event 2024-01-08 · Read 2026-09-26Retrospective · abstract onlyBio

  Medical device filing citing an *Annals of the American Thoracic Society* paper — Inspire Medical Systems, 2024-01-08 · Readout case C089

  Inspire Medical Systems cited a paper published in the Annals of the American Thoracic Society as the basis for its claims in a filing with the U.S. Securities and Exchange Commission. The company read the paper in the order it was written and the scope it actually presented. The stock price movement for one month after the filing was compared to past cases of the same type to determine its relative position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C088Event 2023-11-28 · Read 2026-09-21Retrospective · abstract onlyBio

  Medical device filing citing a European Journal of Nuclear Medicine and Molecular Imaging paper — Perspective Therapeutics, 2023-11-28 · Readout case C088

  In a regulatory filing with the U.S. Securities and Exchange Commission, Perspective Therapeutics cited a paper published in the European Journal of Nuclear Medicine and Molecular Imaging as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the result was written retroactively after knowing the outcome. The paper was read only up to the abstract.

• Readout C087Event 2023-11-13 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal for ImmunoTherapy of Cancer paper — Checkpoint Therapeutics, 2023-11-13 · Readout case C087

  Checkpoint Therapeutics cited a paper published in the Journal for ImmunoTherapy of Cancer as a basis for its claims in a filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C086Event 2023-09-25 · Read 2026-09-26Retrospective · abstract onlyBio

  Medical diagnostic company filing citing a medRxiv paper — SERA Prognostics, 2023-09-25 · Readout case C086

  SERA Prognostics cited a paper published on medRxiv in a regulatory filing submitted to the U.S. Securities and Exchange Commission as the basis for its claims. The company read the way it wrote the paper and the actual scope the paper demonstrated in order. The stock price movement for one month after the filing was compared to past cases of the same type to determine where it stood. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C084Event 2023-05-23 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Nucleic Acids Research paper — Wave Life Sciences, 2023-05-23 · Readout case C084

  Wave Life Sciences cited a paper published in Nucleic Acids Research as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope demonstrated by the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C083Event 2023-05-08 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing an American Journal of Transplantation paper — Tonix Pharmaceuticals, 2023-05-08 · Readout case C083

  Tonix Pharmaceuticals cited a paper published in the American Journal of Transplantation in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C082Event 2023-05-04 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing an American Journal of Transplantation paper — Tonix Pharmaceuticals, 2023-05-04 · Readout case C082

  Tonix Pharmaceuticals cited a paper published in the American Journal of Transplantation in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type, and the position was recorded. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C081Event 2023-04-17 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing an American Journal of Transplantation paper — Tonix Pharmaceuticals, 2023-04-17 · Readout case C081

  Tonix Pharmaceuticals cited a paper published in the American Journal of Transplantation in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement over one month following the filing was compared to past cases of the same type and written accordingly. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C080Event 2023-04-06 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing an International Immunopharmacology paper — PDS Biotechnology, 2023-04-06 · Readout case C080

  PDS Biotechnology cited a paper published in International Immunopharmacology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C079Event 2023-03-14 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing the International Immunopharmacology paper — PDS Biotechnology, 2023-03-14 · Readout case C079

  PDS Biotechnology cited a paper published in International Immunopharmacology in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C078Event 2023-03-09 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing a European Journal of Cancer paper — Moleculin Biotech, 2023-03-09 · Readout case C078

  Moleculin Biotech cited a paper published in the European Journal of Cancer in a regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C077Event 2023-02-28 · Read 2026-09-26Retrospective · abstract onlyBio

  regulatory filing by a medical testing center citing a Journal of Genetic Counseling paper — Natera, 2023-02-28 · Readout case C077

  Natera cited a paper published in the Journal of Genetic Counseling as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C076Event 2023-01-25 · Read 2026-09-23Retrospective · abstract onlyBio

  Biological product filing citing a Science Translational Medicine paper — Inhibikase Therapeutics, 2023-01-25 · Readout case C076

  Inhibikase Therapeutics cited a paper published in Science Translational Medicine in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company's manner of writing the paper and the actual scope presented in the paper were read in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its relative position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C075Event 2023-01-17 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of Allergy and Clinical Immunology paper — Avalo Therapeutics, 2023-01-17 · Readout case C075

  Avalo Therapeutics cited a paper published in the Journal of Allergy and Clinical Immunology as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C074Event 2023-01-10 · Read 2026-09-21Retrospective · abstract onlyBio

  Biological product regulatory filing citing Blood Purification paper — Prokidney, 2023-01-10 · Readout case C074

  Prokidney cited a paper published in Blood Purification in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company's manner of writing the paper and the actual scope of the paper were read in sequence. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C073Event 2022-12-19 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical filing citing an Annals of Oncology paper — Zymeworks, 2022-12-19 · Readout case C073

  Zymeworks cited a paper published in Annals of Oncology in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the paper in the order it was written and the scope it actually demonstrated. The stock price movement for one month after the filing was compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C072Event 2022-11-28 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing Advances in Therapy paper — Praxis Precision Medicines, 2022-11-28 · Readout case C072

  Praxis Precision Medicines cited a paper published in Advances in Therapy as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C071Event 2022-11-15 · Read 2026-09-26Retrospective · abstract onlyBio

  Biological product regulatory filing citing NEJM Evidence paper — Immunitybio, 2022-11-15 · Readout case C071

  Immunitybio cited a paper published in NEJM Evidence in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C070Event 2022-11-09 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing Advances in Therapy paper — Praxis Precision Medicines, 2022-11-09 · Readout case C070

  Praxis Precision Medicines cited a paper published in Advances in Therapy as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C069Event 2022-11-08 · Read 2026-09-26Retrospective · abstract onlyBio

  Medical testing facility filing citing Transplantation paper — Natera, 2022-11-08 · Readout case C069

  Natera cited a paper published in Transplantation in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C068Event 2022-08-08 · Read 2026-09-23Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of Neuroinflammation paper — Vaccinex, 2022-08-08 · Readout case C068

  Vaccinex cited a paper published in the Journal of Neuroinflammation as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C067Event 2022-06-07 · Read 2026-09-22Retrospective · abstract onlyBio

  Regulatory filing citing a Brain Behavior and Immunity paper — Tonix Pharmaceuticals, 2022-06-07 · Readout case C067

  Tonix Pharmaceuticals cited a paper published in Brain Behavior and Immunity as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C066Event 2022-05-17 · Read 2026-09-26Retrospective · abstract onlyBio

  Diagnostic material filing citing a Nature Medicine paper — Lantheus, 2022-05-17 · Readout case C066

  Lantheus cited a paper published in Nature Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C065Event 2022-05-09 · Read 2026-09-21Retrospective · abstract onlyBio

  pharmaceutical filing citing MMWR Morbidity and Mortality Weekly Report paper — Tonix Pharmaceuticals, 2022-05-09 · Readout case C065

  Tonix Pharmaceuticals cited a paper published in MMWR Morbidity and Mortality Weekly Report in its regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C064Event 2022-04-13 · Read 2026-09-26Retrospective · abstract onlyBio

  Pharmaceutical filing citing Scientific American paper — Cartesian Therapeutics, 2022-04-13 · Readout case C064

  Cartesian Therapeutics cited a paper published in Scientific American in a regulatory filing with the U.S. Securities and Exchange Commission. The company's manner of writing the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C062Event 2022-04-06 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical filing citing Scientific American paper — Cartesian Therapeutics, 2022-04-06 · Readout case C062

  Cartesian Therapeutics cited a paper published in Scientific American in a regulatory filing with the U.S. Securities and Exchange Commission. The company's manner of writing about the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C061Event 2022-03-14 · Read 2026-09-25Retrospective · abstract onlyBio

  Regulatory filing by Tonix Pharmaceuticals citing a paper in Nature Structural & Molecular Biology — Readout case C061, 2022-03-14

  Tonix Pharmaceuticals cited a paper published in Nature Structural & Molecular Biology in its regulatory filing with the U.S. Securities and Exchange Commission. The company's manner of writing about the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C060Event 2022-02-16 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Nature Communications paper — Cartesian Therapeutics, 2022-02-16 · Readout case C060

  Cartesian Therapeutics cited a paper published in Nature Communications as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope demonstrated by the paper in sequence. The stock price movement over one month following the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C059Event 2022-01-11 · Read 2026-09-22Retrospective · abstract onlyBio

  pharmaceutical filing citing a JCI Insight paper — Tonix Pharmaceuticals, 2022-01-11 · Readout case C059

  Tonix Pharmaceuticals cited a paper published in JCI Insight in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C058Event 2022-01-04 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a JCI Insight paper — Tonix Pharmaceuticals, 2022-01-04 · Readout case C058

  Tonix Pharmaceuticals cited a paper published in JCI Insight in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C057Event 2021-12-14 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a JCI Insight paper — Tonix Pharmaceuticals, 2021-12-14 · Readout case C057

  Tonix Pharmaceuticals cited a paper published in JCI Insight in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type, and the position was recorded. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C056Event 2021-12-07 · Read 2026-09-25Retrospective · abstract onlyBio

  Medical device regulatory filing citing the Facial Plastic Surgery & Aesthetic Medicine paper — Mimedx, 2021-12-07 · Readout case C056

  Mimedx cited a paper published in Facial Plastic Surgery & Aesthetic Medicine in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claim. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C055Event 2021-11-23 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a JCI Insight paper — Tonix Pharmaceuticals, 2021-11-23 · Readout case C055

  Tonix Pharmaceuticals cited a paper published in JCI Insight in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type and written accordingly. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C054Event 2021-11-04 · Read 2026-09-25Retrospective · abstract onlyBio

  medical testing facility filing citing Clinical Journal of the American Society of Nephrology paper — Natera, 2021-11-04 · Readout case C054

  Natera cited a paper published in the Clinical Journal of the American Society of Nephrology in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope the paper demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C053Event 2021-10-22 · Read 2026-09-25Retrospective · abstract onlyBio

  Biological product regulatory filing citing a Gynecologic Oncology paper — Agenus, 2021-10-22 · Readout case C053

  Agenus cited a paper published in Gynecologic Oncology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C052Event 2021-10-18 · Read 2026-09-22Retrospective · abstract onlyBio

  Regulus Therapeutics regulatory filing citing Nature Genetics paper — Readout case C052, 2021-10-18

  Regulus Therapeutics cited a paper published in Nature Genetics as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope demonstrated by the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C051Event 2021-08-09 · Read 2026-09-25Retrospective · abstract onlyBio

  Medical testing facility filing citing Clinical Cancer Research paper — Celcuity, 2021-08-09 · Readout case C051

  Celcuity cited a paper published in Clinical Cancer Research as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C050Event 2021-08-05 · Read 2026-09-21Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing the *Neurodegenerative Disease Management* paper — Biovie, 2021-08-05 · Readout case C050

  Biovie cited a paper published in Neurodegenerative Disease Management in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C049Event 2021-08-03 · Read 2026-09-25Retrospective · abstract onlyBio

  Medical device regulatory filing citing a Gynecologic Oncology paper — Orasure Technologies, 2021-08-03 · Readout case C049

  Orasure Technologies cited a paper published in Gynecologic Oncology in a regulatory filing with the U.S. Securities and Exchange Commission. The company's manner of writing the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C048Event 2021-07-12 · Read 2026-09-22Retrospective · abstract onlyBio

  pharmaceutical filing citing Expert Opinion on Drug Discovery paper — Immunic, 2021-07-12 · Readout case C048

  Immunic cited a paper published in Expert Opinion on Drug Discovery in a regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C047Event 2021-06-28 · Read 2026-09-25Retrospective · abstract onlyBio

  Diagnostic substance regulatory filing citing a New England Journal of Medicine paper — Intellia Therapeutics, 2021-06-28 · Readout case C047

  Intellia Therapeutics cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C046Event 2021-06-15 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical filing citing FEBS Letters paper — Oncotelic Therapeutics, 2021-06-15 · Readout case C046

  Oncotelic Therapeutics cited a paper published in FEBS Letters in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C045Event 2021-05-17 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal for ImmunoTherapy of Cancer paper — Galectin Therapeutics, 2021-05-17 · Readout case C045

  Galectin Therapeutics cited a paper published in the Journal for ImmunoTherapy of Cancer as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C044Event 2021-04-26 · Read 2026-09-21Retrospective · abstract onlyBio

  pharmaceutical filing citing a Cell paper — Immunome, 2021-04-26 · Readout case C044

  In a regulatory filing with the U.S. Securities and Exchange Commission, Immunome cited a paper published in Cell as the basis for its claims. The company's manner of writing about the paper and the actual scope of the paper were read in sequence. The stock price movement for one month after the filing was compared with past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C043Event 2021-04-07 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical filing citing the American Journal of Obstetrics and Gynecology paper — Evofem Biosciences, 2021-04-07 · Readout case C043

  Evofem Biosciences cited a paper published in the American Journal of Obstetrics and Gynecology as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope the paper demonstrated, in order. The stock price movement for one month after the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C042Event 2021-03-29 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing Cell paper — Immunome, 2021-03-29 · Readout case C042

  In a regulatory filing with the U.S. Securities and Exchange Commission, Immunome cited a paper published in Cell as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. It described where the stock price movement over the following month compared to past similar cases. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C041Event 2021-03-09 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of the Endocrine Society paper — Lumos Pharma, 2021-03-09 · Readout case C041

  Lumos Pharma cited a paper published in the Journal of the Endocrine Society in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C040Event 2021-03-04 · Read 2026-09-25Retrospective · abstract onlyBio

  Journal of Endocrinological Investigation paper cited in pharmaceutical regulatory filing — Lipocine, 2021-03-04 · Readout case C040

  Lipocine cited a paper published in the Journal of Endocrinological Investigation in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the scope the paper actually showed in order. The stock price movement for one month after the filing was written in comparison to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C039Event 2021-03-02 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical filing citing a bioRxiv (Cold Spring Harbor Laboratory) paper — Oncotelic Therapeutics, 2021-03-02 · Readout case C039

  Oncotelic Therapeutics cited a paper published in bioRxiv (Cold Spring Harbor Laboratory) in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the way it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C038Event 2021-02-25 · Read 2026-09-25Retrospective · abstract onlyBio

  Medical device regulatory filing citing a European Urology Focus paper — Teleflex, 2021-02-25 · Readout case C038

  Teleflex cited a paper published in European Urology Focus as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C037Event 2021-02-11 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a New England Journal of Medicine paper — Alkermes, 2021-02-11 · Readout case C037

  Alkermes cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. The stock price movement over one month following the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C036Event 2020-12-23 · Read 2026-09-22Retrospective · abstract onlyBio

  Regulatory filing citing a Genome biology paper — Tonix Pharmaceuticals, 2020-12-23 · Readout case C036

  Tonix Pharmaceuticals cited a paper published in Genome biology in a regulatory filing with the U.S. Securities and Exchange Commission. The company's manner of writing the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C035Event 2020-12-04 · Read 2026-09-22Retrospective · abstract onlyBio

  Regulatory filing citing a Genome biology paper — Tonix Pharmaceuticals, 2020-12-04 · Readout case C035

  Tonix Pharmaceuticals cited a paper published in Genome biology in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company's manner of writing the paper and the actual scope of the paper were read in order. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C034Event 2020-11-09 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Sleep Medicine paper — Avadel Pharmaceuticals, 2020-11-09 · Readout case C034

  Avadel Pharmaceuticals cited a paper published in Sleep Medicine in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C033Event 2020-10-21 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of Diabetes Science and Technology paper — Abbott Laboratories, 2020-10-21 · Readout case C033

  Abbott Laboratories cited a paper published in the Journal of Diabetes Science and Technology in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. The stock price movement for one month after the filing was written in terms of where it ranked compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C032Event 2020-09-21 · Read 2026-09-22Retrospective · abstract onlyBio

  pharmaceutical filing citing a Hepatology Communications paper — Lipocine, 2020-09-21 · Readout case C032

  Lipocine cited a paper published in Hepatology Communications in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C031Event 2020-09-14 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Hepatology Communications paper — Lipocine, 2020-09-14 · Readout case C031

  Lipocine cited a paper published in Hepatology Communications in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C030Event 2020-09-10 · Read 2026-09-25Retrospective · abstract onlyBio

  Biological product filing based on a bioRxiv (Cold Spring Harbor Laboratory) paper — Novavax, 2020-09-10 · Readout case C030

  In a regulatory filing with the U.S. Securities and Exchange Commission, Novavax cited a paper published on bioRxiv (Cold Spring Harbor Laboratory) as the basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C029Event 2020-08-04 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a bioRxiv (Cold Spring Harbor Laboratory) paper — Rigel Pharmaceuticals, 2020-08-04 · Readout case C029

  Rigel Pharmaceuticals cited a paper published on bioRxiv (Cold Spring Harbor Laboratory) in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope presented in the paper in sequence. The stock price movement for one month following the filing was compared to past cases of the same type to determine its relative position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C028Event 2020-08-03 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Hepatology Communications paper — Lipocine, 2020-08-03 · Readout case C028

  Lipocine cited a paper published in Hepatology Communications in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C027Event 2020-06-16 · Read 2026-09-25Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Nature paper — Moleculin Biotech, 2020-06-16 · Readout case C027

  Moleculin Biotech cited a paper published in Nature in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the scope the paper actually showed in order. The stock price movement for one month after the filing was compared to past cases of the same type to determine where it stood. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C026Event 2020-05-20 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a bioRxiv (Cold Spring Harbor Laboratory) paper — Aldeyra Therapeutics, 2020-05-20 · Readout case C026

  Aldeyra Therapeutics cited a paper published in bioRxiv (Cold Spring Harbor Laboratory) in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the way it wrote the paper and the actual scope the paper demonstrated, in order. The stock price movement for one month after the filing was compared to past cases of the same type, and the position was written accordingly. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C025Event 2020-05-12 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical filing citing a BMJ paper — Oncotelic Therapeutics, 2020-05-12 · Readout case C025

  Oncotelic Therapeutics cited a paper published in the BMJ in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in order. The stock price movement over one month following the filing was compared to past cases of the same type, and the position was noted. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C024Event 2020-04-23 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing the Drugs - Real World Outcomes paper — United Therapeutics, 2020-04-23 · Readout case C024

  United Therapeutics cited a paper published in Drugs - Real World Outcomes in a regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C023Event 2020-04-22 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of Heart and Lung Transplantation paper — Immunic, 2020-04-22 · Readout case C023

  Immunic cited a paper published in The Journal of Heart and Lung Transplantation in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C022Event 2020-03-18 · Read 2026-09-22Retrospective · abstract onlyBio

  Biologic product regulatory filing citing a Journal of the American Academy of Dermatology paper — Fresh Tracks Therapeutics, 2020-03-18 · Readout case C022

  Fresh Tracks Therapeutics cited a paper published in the Journal of the American Academy of Dermatology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the scope the paper actually demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C021Event 2020-01-02 · Read 2026-09-22Retrospective · abstract onlyBio

  Biological product filing based on an Alzheimer's Research & Therapy paper — Inmune Bio, 2020-01-02 · Readout case C021

  Inmune Bio cited a paper published in Alzheimer s Research & Therapy in its regulatory filing with the U.S. Securities and Exchange Commission as the basis for its claims. The company read the way it wrote the paper and the actual scope the paper demonstrated in order. The stock price movement for one month after the filing was written in comparison to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C020Event 2019-12-13 · Read 2026-09-24Retrospective · abstract onlyBio

  Medical device regulatory filing citing a New England Journal of Medicine paper — Tandem Diabetes CARE, 2019-12-13 · Readout case C020

  Tandem Diabetes CARE cited a paper published in the New England Journal of Medicine as the basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in order. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C019Event 2019-11-13 · Read 2026-09-22Retrospective · abstract onlyBio

  Electronic medical device filing citing a PLoS ONE paper — Soleno Therapeutics, 2019-11-13 · Readout case C019

  Soleno Therapeutics cited a paper published in PLoS ONE in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the actual scope of the paper in order. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C018Event 2019-10-03 · Read 2026-09-24Retrospective · abstract onlyBio

  Medical device regulatory filing citing the Catheterization and Cardiovascular Interventions paper — Angiodynamics, 2019-10-03 · Readout case C018

  In a regulatory filing submitted to the U.S. Securities and Exchange Commission, Angiodynamics cited a paper published in Catheterization and Cardiovascular Interventions as the basis for its claims. The company read the paper in the order it was written and assessed the scope it actually covered. The stock price movement over the following month was compared to past cases of the same type. This is a retrospective judgment written after the results were known. The paper was read only up to the abstract.

• Readout C017Event 2019-10-02 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical filing citing the Hernia paper — Heron Therapeutics, 2019-10-02 · Readout case C017

  Heron Therapeutics cited a paper published in Hernia as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. The stock price movement for one month after the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C016Event 2019-09-25 · Read 2026-09-24Retrospective · abstract onlyBio

  Electronic medical device filing citing Cephalalgia paper — Electrocore, 2019-09-25 · Readout case C016

  Electrocore cited a paper published in Cephalalgia as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C015Event 2019-05-09 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical filing citing a New England Journal of Medicine paper — Phasebio Pharmaceuticals, 2019-05-09 · Readout case C015

  Phasebio Pharmaceuticals cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope the paper demonstrated, in order. The stock price movement over one month following the filing was compared to past cases of the same type, and the result was written as a hindsight judgment after knowing the outcome. The paper was read only up to the abstract.

• Readout C014Event 2019-05-01 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of the American College of Cardiology paper — Amarin \UK, 2019-05-01 · Readout case C014

  Amarin UK cited a paper published in the Journal of the American College of Cardiology as the basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the scope it actually demonstrated in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C013Event 2019-04-10 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a New England Journal of Medicine paper — Phasebio Pharmaceuticals, 2019-04-10 · Readout case C013

  Phasebio Pharmaceuticals cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type, and the result was written as a hindsight judgment after knowing the outcome. The paper was read only up to the abstract.

• Readout C012Event 2018-07-26 · Read 2026-09-22Retrospective · abstract onlyBio

  Biological product regulatory filing citing a New England Journal of Medicine paper — Biocryst Pharmaceuticals, 2018-07-26 · Readout case C012

  Biocryst Pharmaceuticals cited a paper published in the New England Journal of Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. The stock price movement over the following month was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C011Event 2018-07-24 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Nature Medicine paper — Bioxcel Therapeutics, 2018-07-24 · Readout case C011

  Bioxcel Therapeutics cited a paper published in Nature Medicine as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the actual scope of the paper in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C010Event 2018-06-21 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of Allergy and Clinical Immunology paper — Optinose, 2018-06-21 · Readout case C010

  Optinose cited a paper published in the Journal of Allergy and Clinical Immunology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the way it wrote the paper and the scope the paper actually showed in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C009Event 2018-01-22 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a PLoS ONE paper — Tonix Pharmaceuticals, 2018-01-22 · Readout case C009

  Tonix Pharmaceuticals cited a paper published in PLoS ONE in a regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C008Event 2017-06-14 · Read 2026-09-24Retrospective · abstract onlyBio

  Biotechnology Reports paper-cited pharmaceutical filing — Soligenix, 2017-06-14 · Readout case C008

  Soligenix cited a paper published in Biotechnology Reports as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C007Event 2017-04-28 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical filing citing a Journal of Pain paper — Vistagen Therapeutics, 2017-04-28 · Readout case C007

  Vistagen Therapeutics cited a paper published in the Journal of Pain as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. The stock price movement over one month following the filing was compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C006Event 2016-12-08 · Read 2026-09-24Retrospective · abstract onlyBio

  Journal of Biotechnology paper cited in pharmaceutical regulatory filing — Soligenix, 2016-12-08 · Readout case C006

  Soligenix cited a paper published in the Journal of Biotechnology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope demonstrated by the paper in sequence. It described where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C005Event 2016-08-09 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical Preparations regulatory filing citing a Journal of Clinical Investigation paper — Alaunos Therapeutics, 2016-08-09 · Readout case C005

  Alaunos Therapeutics cited a paper published in the Journal of Clinical Investigation as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which it wrote the paper and the actual scope of the paper in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C004Event 2016-08-04 · Read 2026-09-24Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Journal of the American Society of Nephrology paper — Alnylam Pharmaceuticals, 2016-08-04 · Readout case C004

  Alnylam Pharmaceuticals cited a paper published in the Journal of the American Society of Nephrology as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange Commission. The company read the manner in which the paper was written and the scope it actually demonstrated in sequence. The stock price movement over one month following the filing was compared to past cases of the same type to determine its position. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.

• Readout C001Event 2015-04-22 · Read 2026-09-22Retrospective · abstract onlyBio

  Pharmaceutical regulatory filing citing a Nature paper — Arbutus Biopharma, 2015-04-22 · Readout case C001

  Arbutus Biopharma cited a paper published in Nature in its regulatory filing with the U.S. Securities and Exchange Commission as a basis for its claims. The company read the way it wrote the paper and the scope the paper actually showed in sequence. It noted where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.